New research suggests that patients who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Published data in a leading medical journal demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying these drugs should be aware of the risk of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight in about one and a half years.
Comparing Therapies
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills.
Scientists point out that individuals who shed pounds through lifestyle changes alone typically have a slower creep back—perhaps 100 grams monthly—once they finish.
Understanding the Fast Rebound
Doctors propose the way of the injections is key to understanding the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
The NHS suggest the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts say that, given the significant potential of relapse, the treatment is often life-long.
This view is supported by drug manufacturers, who note that the results "underscore the persistent character of excess weight," akin to managing conditions like high blood pressure.
Patient Accounts
People who have come off the medication describe a sudden return of cravings.
"I experienced something that goes on and you become starving," said an individual.
This difficulty is exacerbated if individuals have not established permanent dietary or behavioural changes during treatment.
Widespread Use
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and lasting health benefits relies on ongoing behavioural management.